香港股市 將在 9 小時 8 分鐘 開市

Roche Holding AG (RHHVF)

Other OTC - Other OTC 延遲價格。貨幣為 USD。
加入追蹤清單
288.90+6.01 (+2.13%)
市場開市。 截至 09:56AM EST。
全螢幕
交易股價資料並非來自所有市場
前收市價282.89
開市285.20
買盤0.00 x 0
賣出價0.00 x 0
今日波幅285.20 - 288.90
52 週波幅252.87 - 334.30
成交量3,030
平均成交量1,982
市值231.842B
Beta 值 (5 年,每月)0.19
市盈率 (最近 12 個月)18.30
每股盈利 (最近 12 個月)15.79
業績公佈日
遠期股息及收益率10.25 (3.62%)
除息日2023年3月16日
1 年預測目標價
  • Financial Times

    Roche: fat fighter drugs buy must precede trial wins

    Novo Nordisk and Eli Lilly are already striding ahead with anti-obesity treatments. Switzerland’s Roche has just boosted its chances of being a contender. It is acquiring US-based obesity drugs developer Carmot Therapeutics for up to $3.1bn.

  • Financial Times

    Roche to buy Carmot for up to $3.1bn as race for obesity drugs intensifies

    Roche has agreed to buy anti-obesity drug developer Carmot Therapeutics for up to $3.1bn, as the Swiss pharmaceutical group joins the industry’s charge into the fast-growing market for weight loss treatments. The acquisition of Carmot, which is based in Berkeley, California, hands Roche a series of assets based on glucagon-like peptide 1 (GLP-1) agonists, which were developed to help control blood sugar levels in people with diabetes. GLP-1s now underpin a weight loss drug, Wegovy, developed by pharmaceutical group Novo Nordisk.

  • Insider Monkey

    Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript

    Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript November 9, 2023 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.05. Operator: Welcome to the Lineage Cell Therapeutics Third Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call […]